In SMA patients, the combination of low SMN protein levels and oxidative stress resulting from mitochondrial dysfunction reportedly leads to increased cell death, which in turn promotes muscle atrophy and cardiovascular abnormalities (Wijngaarde et al. 2017). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.